Developing the first class of ADCs based on NMT inhibition to treat cancer
About Myricx
We are a biotech company, headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs), based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.
Pipeline
At Myricx we are advancing a proprietary pipeline of new generation ADCs to address significant unmet needs in oncology. Our ADCs have demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.
Latest News
- Kadans Science Partner welcomes Myricx Bio to London Innovation Centre 12 September 2024
- Myricx Bio Announces Board Changes 9 July 2024
